This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
On Friday, the Food and Drug Administration issued an emergency authorization for the first at-home test that can detect flu and Covid-19 — but for the test’s maker, Lucira, the long-anticipated authorization may have taken too long. The company filed for bankruptcy on Feb. 22, directly blaming the “protracted” FDA authorization process for the over-the-counter combination test for its financial troubles.
In the last decade, the idea of tapping into the gut has attracted much interest from investors and the public, but recent years have showed that a lot more work needs to be done before such treatments enter the mainstream. This is largely due to the FDA’s rigorous approach to the safety of microbiome therapeutics, which has manifested in clinical holds, resulting in delays that have dimmed the enthusiasm in the space in recent times.
I’ve followed the NAPLEX exam since I graduated in 2009. The NAPLEX was relatively easy from my experience and the experience of many of my classmates. The pass rate that year was an indicator that the NAPLEX was not very difficult. That is not the case anymore. Just looking at the California Board of Pharmacy […] The post What The NAPLEX 2022 Pass Rate Tells Us About 2023 appeared first on Med Ed 101.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to the long-acting drug delivery (LADD) of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases. LADD has emerged as the novel and advanced drug delivery system which manipulate the dosing regimen of the drug in the body in order to sustain its therapeutic level.
Causes of hand tremors | Types of hand tremors | Natural treatments | Other treatments | Is there a cure for hand tremor? | When to see a doctor Tremor is a neurological condition of involuntary muscle contractions that cause shaking movements in one or more body parts. It usually affects the hands, but can also affect the legs, head, vocal cords, and torso.
Dezapelisib is under clinical development by Incyte and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase I drugs for Chronic Lymphocytic Leukemia (CLL) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Dezapelisib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
Dezapelisib is under clinical development by Incyte and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase I drugs for Chronic Lymphocytic Leukemia (CLL) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Dezapelisib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
Overview: What does colon cancer feel like? Colon cancer is a cancer of the large intestine, the last part of the digestive system. Healthcare professionals generally consider it part of a single diagnosis, colorectal cancer, or cancer of the colon and rectum (the last several inches of the colon adjoining the anus). Colorectal cancer is a severe, life-threatening medical condition responsible for about 1 out of 2 cancer deaths in the U.S.
CUE-102 is under clinical development by Cue Biopharma and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CUE-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
Cellular Immunotherapy for Non-Small Cell Lung Cancer is under clinical development by Iovance Biotherapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cellular Immunotherapy for Non-Small Cell Lung Cancer’s drug-specific PTSR and Likelihood of Approval (LoA) scores
EDP-1815 is under clinical development by Evelo Biosciences and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EDP-1815’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Dezapelisib is under clinical development by Incyte and currently in Phase I for Hairy Cell Leukemia. According to GlobalData, Phase I drugs for Hairy Cell Leukemia have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Dezapelisib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
CUE-102 is under clinical development by Cue Biopharma and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase I drugs for Gastroesophageal (GE) Junction Carcinomas have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CUE-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
129 
Let's personalize your content